JFJohan Fenhammar

Johan Fenhammar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Johan Fenhammar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Andersson

    Department of Pediatric Perioperative Medicine and Intensive Care, Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden

    2 shared publications
  • A. Sollevi

    Department of Anaesthesia and Intensive care, Karolinska University Hospital, Stockholm, Sweden

    1 shared publication
  • Alf Sollevi

    Department of Anaesthesiology & Intensive Care, Karolinska University Hospital Huddinge, and Department for Clinical Science Intervention and Technology, Karolinska Institutet, Huddinge, Stockholm, Sweden

    1 shared publication
  • Annika Wernerson

    Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

    1 shared publication
  • E. Weitzberg

    Physiology and Pharmacology, Section for Anaesthesiology and Intensive Care, Karolinska Institutet, Stockholm, Sweden

    1 shared publication
  • Eddie Weitzberg

    Department of Physiology & Pharmacology, Section for Anaesthesiology and Intensive Care, Karolinska Institutet, Stockholm, Sweden

    1 shared publication

Latest Publications

  • Open Access

    Renal effects of treatment with a TLR4 inhibitor in conscious septic sheep

    by Johan Fenhammar, Mats Rundgren, Kjell Hultenby, Jakob Forestier, Micael Taavo, Ellinor Kenne, Eddie Weitzberg, Stefan Eriksson, Volkan Ozenci, Annika Wernerson, et al.

    Acute kidney injury (AKI) is a common and feared complication of sepsis. The pathogenesis of sepsis-induced AKI is largely unknown, and therapeutic interventions are mainly supportive. In the present study, we tested the hypothesis that pharmacological inhibition of Toll-like receptor 4 (TLR4) would improve renal function and reduce renal damage in experimental sepsis, even after AKI had already developed. Sheep were surgically instrumented and subjected to a 36-hour intravenous infusion of live Escherichia coli. After 12 hours, they were randomized to treatment with a selective TLR4 inhibitor (TAK-242) or vehicle. The E. coli caused normotensive sepsis characterized by fever, increased cardiac index, hyperlactemia, oliguria, and decreased creatinine clearance. TAK-242 significantly improved creatinine clearance and urine output. The increase in N-acetyl-beta-D-glucosaminidas, a marker of tubular damage, was attenuated. Furthermore, TAK-242 reduced the renal neutrophil accumulation and glomerular endothelial swelling caused by sepsis. These effects were independent of changes in renal artery blood flow and renal microvascular perfusion in both cortex and medulla. TAK-242 had no effect per se on the measured parameters. These results show that treatment with a TLR4 inhibitor is able to reverse a manifest impairment in renal function caused by sepsis. In addition, the results provide evidence that the mechanism underlying the effect of TAK-242 on renal function does not involve improved macro-circulation or micro-circulation, enhanced renal oxygen delivery, or attenuation of tubular necrosis. TLR4-mediated inflammation resulting in glomerular endothelial swelling may be an important part of the pathogenesis underlying Gram-negative septic acute kidney injury.


  • Open Access

    Endothelin Receptor A Antagonism Attenuates Renal Medullary Blood Flow Impairment in Endotoxemic Pigs

    by Johan Fenhammar, Andreas Andersson, Jakob Forestier, Eddie Weitzberg, Alf Sollevi, Hans Hjelmqvist, Robert Frithiof

    Endothelin-1 is a potent endogenous vasoconstrictor that contributes to renal microcirculatory impairment during endotoxemia and sepsis. Here we investigated if the renal circulatory and metabolic effects of endothelin during endotoxemia are mediated through activation of endothelin-A receptors. A randomized experimental study was performed with anesthetized and mechanically ventilated pigs subjected to Escherichia coli endotoxin infusion for five hours. After two hours the animals were treated with the selective endothelin receptor type A antagonist TBC 3711 (2 mg⋅kg−1, n = 8) or served as endotoxin-treated controls (n = 8). Renal artery blood flow, diuresis and creatinine clearance decreased in response to endotoxemia. Perfusion in the cortex, as measured by laser doppler flowmetry, was reduced in both groups, but TBC 3711 attenuated the decrease in the medulla (p = 0.002). Compared to control, TBC 3711 reduced renal oxygen extraction as well as cortical and medullary lactate/pyruvate ratios (p<0.05) measured by microdialysis. Furthermore, TBC 3711 attenuated the decline in renal cortical interstitial glucose levels (p = 0.02) and increased medullary pyruvate levels (p = 0.03). Decreased creatinine clearance and oliguria were present in both groups without any significant difference. These results suggest that endothelin released during endotoxemia acts via endothelin A receptors to impair renal medullary blood flow causing ischemia. Reduced renal oxygen extraction and cortical levels of lactate by TBC 3711, without effects on cortical blood flow, further suggest additional metabolic effects of endothelin type A receptor activation in this model of endotoxin induced acute kidney injury.


  • The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock

    by J. Fenhammar, A. Andersson, R. Frithiof, J. Forestier, E. Weitzberg, A. Sollevi, H. Hjelmqvist

    Background:Impaired renal microcirculation has been suggested as a factor contributing to the development of renal dysfunction in sepsis. This study was conducted to elucidate the role of endothelin‐1 (ET‐1)in mediating reductions in renal microcirculatory blood flow during endotoxemic shock.Methods:A prospective, randomized, and experimental study was performed with 16 anesthetized and mechanically ventilated pigs. After 2 h of lipopolysaccaride‐induced endotoxemia, eight animals received a bolus dose of the dual endothelin receptor antagonist tezosentan (1 mg/kg), followed by a continuous infusion of 1 mg/kg/h throughout the experiment. Eight animals served as the control group. Renal microcirculation, total renal blood flow, plasma creatinine levels, cardiac index, and mean arterial pressure were measured. Plasma samples were collected for the measurement of tumor necrosis factor α (TNF‐α), interleukin‐6 (IL‐6), interleukin‐10 (IL‐10), ET‐1, angiotensin II, and aldosterone.Results:Endotoxin infusion resulted in a state of circulatory shock with impairment of renal microcirculation. An increase in the plasma levels of TNF‐α, IL‐6, IL‐10, ET‐1, angiotensin II, and aldosterone was also observed.Tezosentan attenuated the decrease in renal microcirculation and renal blood flow, and attenuated the increase in plasma creatinine. Treatment with tezosentan did not significantly affect the plasma cytokine, angiotensin II, or aldosterone response to endotoxemia.Conclusion:These results indicate that treatment with the dual endothelin receptor tezosentan in endotoxemic shock attenuates the reduction of renal microcirculation and total renal blood flow independently of plasma changes in the renin–angiotensin–aldosterone system or early plasma cytokine response.